The AQUATIC trial (2025) was a double-blind, randomized, placebo-controlled study that evaluated the effect of adding aspirin to long-term oral anticoagulation in patients with chronic coronary syndrome (CCS) at high atherothrombotic risk. A total of 872 patients on oral anticoagulation … Read More
eliquis
ARCADIA Trial: Apixaban After Cryptogenic Stroke
The ARCADIA trial, published in JAMA in 2024, compared the efficacy of apixaban versus aspirin in preventing recurrent strokes in patients with cryptogenic stroke and atrial cardiopathy. Key Findings: Conclusion: In patients with cryptogenic stroke and evidence of atrial cardiopathy … Read More
Navigating the New Era: Landmark Clinical Trials on Eliquis (Apixaban) for Anticoagulation in Atrial Fibrillation
Atrial fibrillation (AFib) is a prevalent cardiac arrhythmia that significantly elevates the risk of stroke and systemic embolism. As a result, effective anticoagulation therapy is crucial for managing AFib patients. Over the past decade, novel oral anticoagulants (NOACs) have challenged … Read More
AMPLIFY Trial: Apixaban for acute VTE
2013 AMPLIFY TRIAL Oral Apixaban for the Treatment of Acute Venous Thromboembolism double-blind, multicenter, randomized controlled trial IM Objective: To determine if apixaban is non-inferior to conventional therapy with LMWH in patients with pulmonary embolism or proximal deep venous thrombosis … Read More
ADAM VTE Trial Summary: Apixaban in Cancer-associated VTE
2019 ADAM VTE TRIAL Apixaban and dalteparin in active malignancy-associated venous thromboembolism multicenter, randomized, open-label superiority trial 287 patients 0 Objective: To study side effects of and compare apixaban and dalteparin in reducing blood clots in patients with cancer-related VTE. … Read More